Chapter 17 — Key Takeaways

BPC-157 — The "Healing Peptide"

The core claims

Two facts, both true, and the chapter's whole job is showing they do not conflict. There is a substantial animal literature on BPC-157 spanning tendon and ligament healing, gastrointestinal protection, vascular and angiogenic responses, and neuroprotection, from more than one research group, in peer-reviewed journals, using standard models with control arms and blinded outcome assessment. And as of this writing in 2026, there is no completed, peer-reviewed, randomized controlled human trial of BPC-157 for any indication in the published literature, and no published Phase I safety study.

An impressive animal result is the normal starting condition of a compound that will not work in humans — and of one that will. Roughly nine in ten compounds entering human trials never reach approval, and those had already cleared preclinical work. The animal result does not discriminate. Animal research generates candidates; humans adjudicate them. BPC-157 has generated a candidate. Nobody has adjudicated it.

Fifteen residues, read structurally, tell you a lot and settle nothing. GEPPPGKPADDAGLV, about 1,419 Da: four prolines including a run of three (rigid, no alpha helix through that region), three glycines (hinges), two aspartates and a glutamate (net negative charge), one lysine (the chemical handle nobody has commercially used). Real information, obtained without any biology — and silent on efficacy.

No receptor has been definitively established. Proposed mechanisms — nitric-oxide-related signaling, growth-factor and angiogenic signaling — are inferred from downstream observations in animal models, not derived from an identified target. The dossier's Field 3 entry is "not established." This also caps how much mechanistic argument is worth: Chapter 5's rule 3 forbids upgrading on mechanism, and here even the mechanism is an inference.

The name tells you about regulation, not pharmacology. BPC-157 has only a laboratory code. Generic names are assigned during serious clinical development, so the absence of one is strong evidence about regulatory history and no evidence about pharmacology. Read the other way, it is a non sequitur.

Four structural problems separate this literature from a human answer, and none is fixed by better animal work. Different biology (and, uniquely here, no identified receptor to compare across species). Different disease and different endpoint (a model captures a piece; a rat cannot report pain or function). Different dose (allometric scaling is approximate, and there is no human pharmacokinetic study to anchor it). And different publication pressure — preclinical work is overwhelmingly unregistered, so the published record is a filtered sample from a population of unknown size, and consistency is exactly what a filter produces.

The transected tendon and the worn tendon may be different diseases, not the same one at different scales. The rodent model is acute, complete, surgical, with a known time zero, in a healthy young animal under controlled activity. Human tendinopathy is chronic, partial, degenerative, developed over months or years, often with abnormal neovascularization already present, in someone who keeps loading the limb. Someone claiming the first predicts the second owes an argument for why.

Stability is not bioavailability. BPC-157's proline-rich structure has genuinely been argued to confer protease resistance — a reasonable chemical claim. It addresses barriers 1–3 of Chapter 4's five and says nothing about barrier 4, permeability, which is a different physical property. A perfectly stable molecule that cannot cross the intestinal epithelium has zero systemic bioavailability. A seller owes: which barrier, how, and a measured human bioavailability figure.

"No reported harm" and "shown to be safe" are different sentences. There is no published human safety data of any kind. Absence of reports is close to uninformative where there is no systematic collection, no reporting pathway that fits an unapproved compound, strong disincentives to disclosure, and no denominator. Separately, gray-market material carries identity, purity, potency, sterility, and endotoxin risks entirely independent of the molecule's pharmacology.

The ratings issued in this chapter

One molecule, two claims, two ratings — Chapter 5's rule 6. They happen to match, and the reasoning behind them is not identical.

The sentence that must not be blurred

❌ describes the state of the evidence, not the state of the molecule.

It does not say BPC-157 does nothing; that is not established either. It does not license "it's a scam" — the animal work is real and the researchers are doing science. It does not license "the evidence just hasn't caught up," which smuggles in the conclusion that the trial, if run, would be positive. And it does not license contempt for anyone using the compound.

Writing an honest ❌ — the six moves

1. State the strongest true case for. In full, not in a subordinate clause. Would an informed advocate recognize their own position?
2. State the evidence situation in one sentence, with a date. Flat tone. If it takes a paragraph, you are arguing rather than reporting.
3. Name the rung. And note that rungs are not reached by accumulating studies on the rung below.
4. Say what the rating does not claim. In its own sentence. This is the move that gets cut for space, and it is what separates a rating from a verdict.
5. Name the falsifier. Specific enough to hand to someone who could run it. "More research is needed" is a way of not having one.
6. Read it back as the person using the compound. Where you flinch, ask whether the flinch came from a fact or from your tone. Facts stay; tone gets rewritten.

What would change the rating

A randomized, double-blind, placebo-controlled trial in adults with chronic mid-portion Achilles tendinopathy; all participants on a standardized progressive loading program so the question is incremental benefit over what already works; primary endpoint a validated patient-reported function score at a pre-specified timepoint; powered for a difference exceeding the instrument's minimal clinically important difference; pre-registered. Exceeds MCID → ⚠️. Independently replicated → ✅. Adequately powered null → a better, more informative ❌. Underpowered or with a surrogate endpoint → nothing changes. A Phase I with human pharmacokinetics would be a meaningful addition on its own.

Why it has not been run: the compound is effectively unpatentable, no regulatory obligation attaches to it, and an established market already sells it without evidence. No party has an incentive to fund the trial that could show it does not work. That is a structural observation about incentives, not an accusation about anyone's conduct — and the realistic route out is an academic, governmental, or philanthropic funder with no stake in the answer.

The single most portable thing in the chapter

The ten-minute check. PubMed: search the compound, apply the Randomized Controlled Trial article filter and the Humans species filter, then open whatever survives and read the methods for the sentence naming the subjects. ClinicalTrials.gov: search the compound and read the status field, then look for posted results — registered, run, completed, results-posted, and published are five different things. Widen to the WHO ICTRP and the EU register. Write down the date and what you found.

It costs ten minutes, it works on every compound in Part III, and it moves you permanently out of the population that has to be told what the evidence says.

Connections

• Chapter 1 §1.2 supplied the structural read of the sequence; §1.8 supplied the naming distinction this chapter insists on preserving exactly.
• Chapter 4 supplied the five barriers that make §17.8 decidable without any clinical data.
• Chapter 5 supplied the ladder, the five reasons, the base rate, the rating rules, and the orphan-compound problem that explains §17.11.
• Chapter 6 supplied the five-stage pipeline that Case Study 2 runs on this compound — and the observation that the pipeline works better when stage 1 is genuinely good, because the citations survive checking.
• Chapter 18 applies this chapter's whole procedure to TB-500 and thymosin β4, with much less help.
• Chapters 19 and 34 cover the gray market and what is actually in a vial — risks entirely independent of the pharmacology.
• Chapter 39 covers the conversation with a clinician, including how to raise a compound you expect them to react badly to.